|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Sheba Medical Center |
|---|---|
| Information provided by: | Sheba Medical Center |
| ClinicalTrials.gov Identifier: | NCT00496925 |
Purpose
We examine the usage of Dopamine blockers in OCD patients. We want to examine their frequency of usage, compare the course of the disease between those who receive and those who do not receive Dopamine blockers, and efficacy of the treatment.
The study will be done in two stages: 1. Collecting information the usage of Dopamine blockers from 150 OCD patients' files. 2. interviewing 60 patients to see the difference those who receive and those who do not receive Dopamine blockers in their current severity of disease.
| Condition |
|---|
|
Obsessive Compulsive Disorder |
| Study Type: | Observational |
| Study Design: | Cross-Sectional, Defined Population, Retrospective Study |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria: - DSM-IV diagnosis of OCD
Contacts and Locations| Contact: Leah Fostick, PhD | +972-3-5357805 | Leah.Fostick@sheba.health.gov.il |
| Israel | |
| Chaim Sheba Medical Center | |
| Ramat-Gan, Israel, 52621 | |
| Principal Investigator: | Joseph Zohar, MD | Chaim Sheba Medical Center |
More Information
| Study ID Numbers: | SHEBA- 07-4651-JZ-CTIL |
| Study First Received: | July 4, 2007 |
| Last Updated: | July 16, 2007 |
| ClinicalTrials.gov Identifier: | NCT00496925 History of Changes |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
|
Dopamine Anxiety Disorders Mental Disorders Dopamine Agents Obsessive-Compulsive Disorder |
|
Anxiety Disorders Mental Disorders Obsessive-Compulsive Disorder |
